Gilead­'s new­ly de­part­ed R&D chief re-emerges as CEO of a ri­val hep B biotech look­ing to make a come­back

4 years ago
People

Loxo chief Josh Bilenker steps in (tem­porar­i­ly) to head on­col­o­gy R&D at Eli Lil­ly as Levi Gar­raway steps out

4 years ago
People
Pharma

Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

4 years ago
R&D

Faced with an­oth­er ethics scan­dal, No­var­tis CEO Vas Narasimhan as­sures an­a­lysts they tried to do 'the right thing'

4 years ago
Pharma
FDA+

Gilead faces a hur­dle in its race for big, add-on OK for De­scovy as gener­ic Tru­va­da ri­vals loom

4 years ago
R&D
Pharma

Sanofi, Re­gen­eron post back-to-back wins with new OK and a fresh round of pos­i­tive PhI­II da­ta for their block­buster growth fran­chise

4 years ago
R&D

Close to a decade af­ter Eli Lil­ly killed it, Jef­frey Blue­stone's 'break­through' drug is back and be­ing steered to the FDA

4 years ago
R&D
FDA+

Join­ing Chang and Bellde­grun, Rafael Ama­do takes a lead­ing R&D post in the next big cell ther­a­py rev­o­lu­tion

4 years ago
People
Cell/Gene Tx

David Apelian to steer TCR play at Pitt spin­out; Third Rock scoops Il­lu­mi­na ex­ec as CEO of can­cer de­tec­tion up­start

4 years ago
Peer Review

Bio­Marin ex­ecs make their case for he­mo­phil­ia gene ther­a­py as fret­ful an­a­lysts start to hedge their bets

4 years ago
R&D

At new­ly rechris­tened Rakuten Med­ical, Japan­ese bil­lion­aire Mik­i­tani ups the ante with an­oth­er megaround

4 years ago
Financing

PD-L1, CD47 and now CD24? Star Stan­ford I/O sci­en­tist Irv Weiss­man points to a ‘ma­jor’ new can­cer tar­get

4 years ago
People
Discovery

Arie Bellde­grun and the crew at Vi­da reap a $600M har­vest for fund II — and they've got LA in their sights

4 years ago
Financing

FDA chief backs 2 new path­ways to spur drug im­por­ta­tion — but an­a­lysts shrug it all off

4 years ago
People
Pharma

Gilead chief Daniel O’Day isn’t done mak­ing head­lines — with more R&D deals and lots of new hires to come

4 years ago
People
Deals

Ped­al to the met­al, Am­gen fi­nal­ly has a hot new drug star on its hands — and they have some news

4 years ago
R&D

Eli Lil­ly ax­es an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic pro­gram in lat­est pipeline cleanup

4 years ago
R&D

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

4 years ago
Bioregnum
Opinion

What is Pfiz­er go­ing to buy next? Al­bert Bourla out­lines his M&A strat­e­gy in the post-Up­john era

4 years ago
Deals
Pharma

No­var­tis’ star block­buster flunks close­ly watched PhI­II — but they may file for key add-on OK any­way

4 years ago
R&D

Failed PhI­I­Is af­ter a re­jec­tion by the FDA spur Sanofi to dump its $1.7B deal with Lex­i­con on di­a­betes drug — shares crash

4 years ago
Deals
R&D

Ab­b­Vie scraps an an­ti-tau study, and that may fore­tell more big trou­ble for a be­lea­guered Bio­gen

4 years ago
R&D

Ver­tex rush­es to as­sure Wall Street that Jeff Lei­den is keep­ing a hand on the reins as one an­a­lyst ques­tions suc­ces­sion plans

4 years ago
People

The top 10 pipeline blowups, set­backs and sna­fus for H1 2019

4 years ago
R&D
Special
First page Previous page 186187188189190191192 Next page Last page